十二指肠胃食管反流患病率、症状、食管病变及治疗的系统综述
该系统综述检索Pubmed和MEDLINE至2020年10月的英文全文,纳入35项分析GERD患者DGER患病率的研究。Bilitec检测的DGER患病率在全部GERD为10%-97%,NERD为10%-63%,糜烂性食管炎为22%-80%,Barrett食管为50%-100%;PPI治疗可降低DGER,但DGER不能解释PPI治疗下持续症状。
要点
- DGER患病率随食管病变加重而升高,Barrett食管可达50%-100%。
- PPI治疗下有无症状患者的DGER存在或程度无差异。
- PPI是DGER最常评估的治疗,所有研究显示PPI治疗后DGER降低。
核心结论
- DGER患病率随食管病变越严重而越高,且不能解释PPI治疗下持续的症状。
- PPI似乎对治疗DGER有效,DGER仍是GERD患者的重要考虑因素,未来治疗值得更多研究。
研究设计与样本
- 系统综述,检索Pubmed和MEDLINE至2020年10月的英文全文文章。
- 纳入35项分析GERD患者DGER患病率的研究,其中15项评估NERD、17项评估糜烂性食管炎、23项评估Barrett食管、13项评估DGER治疗。
主要发现
- Bilitec检测的DGER患病率在全部GERD患者中为10%-97%。
- DGER患病率在NERD中为10%-63%,在糜烂性食管炎中为22%-80%,在Barrett食管中为50%-100%。
- PPI治疗下无症状与有症状患者的DGER存在或程度无差异。
- 所有评估PPI治疗DGER的研究均显示PPI治疗后DGER降低。
关键数值与推荐
- DGER患病率按Bilitec检测评估:全部GERD 10%-97%,NERD 10%-63%,糜烂性食管炎22%-80%,Barrett食管50%-100%。
临床怎么用
- 对GERD患者应考虑DGER可能,尤其病变越严重时患病率越高。
- PPI可用于降低DGER,但DGER不能解释PPI治疗下持续的症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of duodenogastroesophageal reflux (DGER) and its effect on symptoms and oesophageal lesions in gastroesophageal reflux disease (GERD) is unclear. AIMS: To conduct a systematic review to determine the prevalence of DGER among patients with GERD, the effect of DGER on symptoms and oesophageal lesions, and the treatment of DGER. METHODS: We searched Pubmed and MEDLINE for full text, English language articles until October 2020 that evaluated DGER prevalence among patients with GERD, the effect of DGER on symptoms and oesophageal lesions, and the treatment of DGER. RESULTS: We identified 3891 reports and included 35 which analysed DGER prevalence in GERD, 15 which evaluated its effect in non-erosive reflux disease (NERD), 17 on erosive oesophagitis, 23 in Barrett's, and 13 which evaluated the treatment of DGER. The prevalence of DGER, when evaluated by Bilitec, among all GERD patients ranged from 10% to 97%, in NERD 10%-63%, in erosive oesophagitis 22%-80% and in Barrett's 50%-100%. There were no differences in the presence or degree of DGER among patients who were asymptomatic or symptomatic on proton pump inhibitors (PPI). The most commonly evaluated treatments for DGER were PPIs and DGER reduced post-PPI therapy in all studies. CONCLUSIONS: The prevalence of DGER increased with more advanced oesophageal lesions and did not explain persisting symptoms among patients taking PPI therapy. PPIs appear to be effective in the treatment of DGER. DGER remains an important consideration in patients with GERD and future therapies deserve more study.
引用
- Basnayake C, Geeraerts A, Pauwels A, et al. Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment. Aliment Pharmacol Ther. 2021. PMID: 34313333. doi:10.1111/apt.16533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。